SELLAS Life Sciences Reports Q3 2026 Results and $134.7 Million Cash Position

SELLAS Life Sciences reported a third-quarter 2026 net loss of $10.1 million, or $0.05 per share, compared with a $6.8 million loss, or $0.06 per share, a year earlier. Research and development and general and administrative expenses increased year over year. The company ended September with $134.7…